Top Markets
Coin of the day
Gongwin Biopharm Holdings Co., Ltd. Gongwin Biopharm Holdings Co., Ltd.

Gongwin Biopharm Holdings Co., Ltd.

6617
Rangering i aksjer #13752
Gongwin Biopharm Holdings Co., Ltd. is a clinical-stage biopharmaceutical... Gongwin Biopharm Holdings Co., Ltd. is a clinical-stage biopharmaceutical company specializing in the development of oncology therapeutics. The company's robust pipeline features several drug candidates, including PTS302, which has successfully concluded Phase III clinical trials for lung cancer. Additionally, PTS100 is currently progressing through Phase II clinical trials for liver cancer, while PTS-02 is being developed to address adenoid cystic carcinoma, and PTS500 targets malignant pleural effusion. Established in 2014, Gongwin Biopharm is headquartered in Taipei, Taiwan.
Aksjekurs
$3.83
Markedsverdi
$464.45M
Endring (1 dag)
-1.63%
Endring (1 år)
17.17%
Land
TW
Handel Gongwin Biopharm Holdings Co., Ltd. (6617)

Kategori

P/B-forhold for Gongwin Biopharm Holdings Co., Ltd. (6617)
P/B-forhold per 2026 TTM: 0
Ifølge Gongwin Biopharm Holdings Co., Ltd. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for Gongwin Biopharm Holdings Co., Ltd. fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
-24.3279 -
US
- -
US
-19.2508 -
US
- -
US
5.5898 -
AU